Andrew Yee, MD
Enriched profileClinical Director, Center for Multiple Myeloma; Assistant Professor of Medicine, Harvard Medical School · Massachusetts General Hospital Cancer Center
Andrew Yee is Clinical Director, Center for Multiple Myeloma; Assistant Professor of Medicine, Harvard Medical School at Massachusetts General Hospital Cancer Center. OpenAlex indexes 314 publications with 6,505 citations (h-index 41); ClinicalTrials.gov lists 11 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 15 Oct 2026
Andrew Yee, MD, is Clinical Director, Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center. The public record shows 314 publications with 6,505 citations (h-index 41), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, CAR-T cell therapy research. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 16 companies.
- Most recent indexed publication: 2026 · Blood
- Top research focus: Multiple Myeloma Research and Treatments
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 16 companies
Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 29 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 99.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 15 Oct 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
Sponsor: Massachusetts General Hospital
- Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
Sponsor: Massachusetts General Hospital
- Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Sponsor: Massachusetts General Hospital
Industry payments
Updated 15 Oct 2026
16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Janssen Research & Development, LLCProgram year20253 payments$19,516openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20252 payments$15,784openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
22.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor22.5%Acyclovir100%Part D≥29 patientsNervous system
22.2%Opioid Agonist9.9%Oxycodone Hcl100%Part D≥18 patientsBenzodiazepine7%Lorazepam100%Part D≥11 patients+ 1 more class in this area
Sensory organs
16.2%Corticosteroid16.2%Dexamethasone100%Part D≥26 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 15 Oct 2026
70 congress contributions (2010–2025) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:
- Implementing the bispecific outpatient safe step-up (BOSS) program for elranatamab in ambulatory treatment of multiple myeloma.
ASCO Annual Meeting
ASCO2025Co-author - Deciphering the role of EP300 in maintaining the enhancer landscape and lineage-specific epigenetic vulnerability in multiple myeloma
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 15 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.
Nature communications
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)Network
Updated 15 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 15 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/andrew-j-yee-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - X / Twitter
x.com/andrew02114
Mentions by others
where others cite or feature them- Other
thebloodline.org/213e213
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thebloodline.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - X / Twitter
X/Twitter handle @andrew02114, quoted by OncLive discussing individualized treatment approach to myeloma, tagged with @MGHCancerCenter
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 15 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Fellowship
Hematology & Medical Oncology, Brigham and Women's Hospital / Dana-Farber Cancer Institute combined program
2007verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.massgeneralbrigham.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.massgeneralbrigham.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.massgeneralbrigham.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.massgeneralbrigham.org ↗
Media & interviews
press, podcasts and appearances- OncLive video series
multiple recorded interviews on multiple myeloma treatment topics (e.g. "Dr. Yee on Treatment Considerations in Relapsed/Refractory Multiple Myeloma")
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Featured guest
"Venetoclax for Multiple Myeloma in the Post-CANOVA Era", Oncology Data Advisor video interview
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncdata.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Noopur Raje, MD
Massachusetts General Hospital Cancer Center
Jacob Soumerai, MD
Massachusetts General Hospital Cancer Center
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens